{"disease":{"id":"dravet-syndrome","name":"Dravet syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"fenfluramine","indication_name":"Dravet syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fintepla","generic_name":"FENFLURAMINE","company_name":"UCB","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"fenfluramine","quality_score":10,"revenue":null,"mechanism":"Fintepla works by binding to the Alpha-1B adrenergic receptor, which helps regulate the activity of certain neurons in the brain."},{"drug_id":"fenfluramine","indication_name":"Seizures associated with Dravet syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fintepla","generic_name":"FENFLURAMINE","company_name":"UCB","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"fenfluramine","quality_score":10,"revenue":null,"mechanism":"Fintepla works by binding to the Alpha-1B adrenergic receptor, which helps regulate the activity of certain neurons in the brain."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT02224573","title":"An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":681,"lead_sponsor_name":"GW Research Ltd","has_results":true},{"nct_id":"NCT03936777","title":"A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"Zogenix, Inc.","has_results":true},{"nct_id":"NCT06504511","title":"SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT02823145","title":"An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":375,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":true},{"nct_id":"NCT05163314","title":"A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":352,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02826863","title":"A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":true},{"nct_id":"NCT02682927","title":"A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":true},{"nct_id":"NCT05982717","title":"A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02224703","title":"GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT06660394","title":"A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Longboard Pharmaceuticals","has_results":false},{"nct_id":"NCT03635073","title":"A Study of Soticlestat in Adults and Children With Rare Epilepsies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":156,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05044819","title":"Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT04462770","title":"A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Epygenix","has_results":false},{"nct_id":"NCT04940624","title":"A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03650452","title":"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02091375","title":"Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT05544058","title":"Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Biocodex","has_results":false},{"nct_id":"NCT02896608","title":"Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT05472389","title":"Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02926898","title":"A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":true},{"nct_id":"NCT04442295","title":"An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Stoke Therapeutics, Inc","has_results":false},{"nct_id":"NCT04740476","title":"An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Stoke Therapeutics, Inc","has_results":false},{"nct_id":"NCT04537832","title":"Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies","phase":"","overall_status":"TERMINATED","enrollment_count":58,"lead_sponsor_name":"Encoded Therapeutics","has_results":false},{"nct_id":"NCT05364021","title":"Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Longboard Pharmaceuticals","has_results":false},{"nct_id":"NCT03857451","title":"Treatment of Gait Disorders in Children With Dravet Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT07251673","title":"Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05626634","title":"Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Longboard Pharmaceuticals","has_results":false},{"nct_id":"NCT05651204","title":"GABA Biomarkers in Dravet Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Cook Children's Health Care System","has_results":false},{"nct_id":"NCT02091206","title":"A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT07013331","title":"A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06118255","title":"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"UCB BIOSCIENCES, Inc.","has_results":false},{"nct_id":"NCT07176832","title":"Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Biocodex","has_results":false},{"nct_id":"NCT04069689","title":"Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Epygenix","has_results":false},{"nct_id":"NCT06401538","title":"BMB-101 in Absence Epilepsy and DEE","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Bright Minds Biosciences Pty Ltd","has_results":false},{"nct_id":"NCT07225231","title":"Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Byteflies","has_results":false},{"nct_id":"NCT06371794","title":"EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":16,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05560282","title":"Fenfluramine for Adult Dravet Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03467113","title":"A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":false},{"nct_id":"NCT03299842","title":"A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":true},{"nct_id":"NCT04485104","title":"Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT02815540","title":"The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Gillette Children's Specialty Healthcare","has_results":true},{"nct_id":"NCT06422377","title":"A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05140122","title":"LEONIDaS Caregivers Study","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06395792","title":"A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02318563","title":"Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"INSYS Therapeutics Inc","has_results":false},{"nct_id":"NCT01835314","title":"Compassionate Use of Stiripentol in Dravet Syndrome","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04437004","title":"Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT01983722","title":"Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT03780127","title":"ZX008 Expanded Access Protocol","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Zogenix, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}